# Applied Genetic Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/applied-genetic-technologies

- Industry: Biotechnology
- Headquarters: Alachua, US
- Website: www.agtc.com
- Total disclosed funding: $54M
- Latest round: Series B (Apr 9, 2013)
- Investors on record: 7

## About

Applied Genetic Technologies Corp. is a biotechnology company focused on developing innovative gene therapies to treat genetic diseases, particularly in the field of ophthalmology.Founded in 1999 and headquartered in Alachua, US, Applied Genetic Technologies Corp. specializes in gene therapy solutions. The company has undergone various strategic initiatives to advance its research in ocular conditions. Mohammed Abdulghani is one of the founders, while Sue Washer serves as the CEO. The firm raised USD 23.30 mn in its most recent funding round, transitioning from Public to Private, with Syncona as the investor. The firm has successfully completed 15 deals, with the latest deal occurring on March 26, 2014, bringing the total amount raised to USD 23.30 mn.Applied Genetic Technologies Corp. focuses on developing gene therapies for retinal diseases, primarily targeting X-Linked Retinitis Pigmentosa (XLRP), Dry Age-related Macular Degeneration (dAMD), and Cone Rod Dystrophy (CRD). Its gene therapies aim to restore vision by enabling patients to produce essential proteins through modified cells. The company is actively involved in Phase 2/3 clinical trials for XLRP, expanding its reach across North America, Europe, and parts of Asia.In 2022, Applied Genetic Technologies Corp. reported revenue of USD 325,000 and an EBITDA of USD -63,970,000. Revenue is primarily generated through partnerships for clinical trials and collaborations with healthcare providers, reflecting the company's focus on advancing its gene therapy products through direct-to-consumer and B2B interactions.The company plans to utilize recent funding to enhance its clinical and preclinical studies for its gene therapy offerings, particularly focusing on ongoing trials for XLRP and the Phase 1/2 trials for Achromatopsia (ACHM). With recent funds raised, Applied Genetic Technologies Corp. aims to further develop its therapies and explore additional treatments for eye diseases. The company also intends to expand its market presence globally, targeting specific markets in North America, Europe, and Asia by 2024.

## Funding rounds

- Series B, Apr 9, 2013, $18M — Alta Partners, Intersouth Partners
- Series B, Nov 15, 2012, $7.8M — Alta Partners, Intersouth Partners, InterWest Partners, SR One, OUP (Osage University Partners), MedImmune Ventures
- Series A, Jun 21, 2007, $7.5M — Intersouth Partners, InterWest Partners, Skyline Ventures, MedImmune Ventures
- Series A, Mar 31, 2006, $5M — Intersouth Partners, InterWest Partners, Skyline Ventures, MedImmune Ventures
- Series A, Dec 1, 2003, $15M — Intersouth Partners, InterWest Partners, Skyline Ventures, MedImmune Ventures

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series A, Series B
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series A, Series B
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B